Document is current
Any future updates will be listed below
-
Authors
Eck, Ruben J. http://orcid.org/0000-0001-7440-2465
Hulshof, Lisa http://orcid.org/0000-0002-9665-4476
Wiersema, Renske http://orcid.org/0000-0003-2413-2852
Thio, Chris H. L. http://orcid.org/0000-0003-2623-7172
Hiemstra, Bart http://orcid.org/0000-0001-6547-2138
van den Oever, Niels C. Gritters
Gans, Reinold O. B. http://orcid.org/0000-0001-5481-2387
van der Horst, Iwan C. C. http://orcid.org/0000-0003-3891-8522
Meijer, Karina http://orcid.org/0000-0001-9447-0465
Keus, Frederik http://orcid.org/0000-0003-1516-1475
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03773939 at ClinicalTrials.govDocuments that mention this clinical trial
Incidence, prognostic factors, and outcomes of venous thromboembolism in critically ill patients: data from two prospective cohort studies
https://doi.org/10.1186/s13054-021-03457-0
- License Information
-
More Information
Article History
Received: 2 September 2020
Accepted: 1 January 2021
First Online: 12 January 2021
Ethics approval and consent to participate
: In unresponsive patients, informed consent was first obtained from the legal representatives. Consent for the use of the study data was asked at a later time if the patient recovered consciousness. If the patient died before consent was obtained, the study data was used, and the legal representatives were informed of the study. The local institutional review board (METc Groningen) approved both cohort studies (2015/004 and 2018/203) and the current analysis (2019/078).
: Not applicable.
: KM reports grants from Bayer, Sanquin, and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, BMS, and Aspen; travel support from Bayer, and consulting fees from Uniqure outside the submitted work; other authors have disclosed no potential conflicts of interest.
